Market Research Report
Global Diabetic Nephropathy Market 2018-2022
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||298333|
|Published||Content info||98 Pages
Delivery time: 1-2 business days
|Global Diabetic Nephropathy Market 2018-2022|
|Published: December 5, 2018||Content info: 98 Pages||
Rise in incidence of diabetes to push growth in the market. Globally, there has been a rise in the incidence and prevalence of diabetes, which has resulted in the occurrence of chronic kidney disease in patients. Technavio's analysts have predicted that the diabetic nephropathy market will register a CAGR of almost 34% by 2022.
Increasing incidence of diabetic nephropathy among diabetic patients
The incidence of diabetic nephropathy was observed to be much higher in freshly diagnosed cases of type 2 diabetes patients. The factors associated with the rise of incidence of nephropathy are hypertension, hypercholesterolemia, and obesity.
Growing economic burden of diabetic nephropathy
Diabetic nephropathy is a complication associated with diabetes mellitus. The cost associated with diabetic nephropathy increases gradually with the progression of disease due to the associated cost drivers such as dialysis and hospitalization.
For the detailed list of factors that will drive and challenge the growth of the diabetic nephropathy market during the 2018-2022, view our report.
The market appears to be fragmented and with the presence of several companies including Techman-Head Group and Brackett Aircraft Company the competitive environment is quite intense. Factors such as the increasing incidence of diabetic nephropathy among diabetic patients and the rise in incidence of diabetes, will provide considerable growth opportunities to diabetic nephropathy manufactures. AstraZeneca, Merck, and Sanofi are some of the major companies covered in this report.